Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

被引：0
|
作者：
Sui, Weiwei [1 ,2 ]
An, Gang [3 ]
Deng, Shuhui [4 ,5 ]
Xu, Yan [4 ,5 ]
Hao, Mu [6 ,7 ]
Fu Mingwei [6 ,7 ]
Wang, Tingyu [6 ,7 ]
Yi, Shuhua [4 ,5 ]
Zhao, Yaozhong [8 ,9 ,10 ]
Zou, Dehui [4 ,5 ]
Li, Zengjun [11 ]
Qiu, Lugui [6 ,7 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[8] Chinese Acad Med Sci, Hematol Blood Dis Hosp, Tianji, Tianjing, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[10] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
Real-world; Ixazomib; multiple myeloma;
D O I：
10.1182/blood-2019-126718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5581
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real World Data on the Efficacy and Safety of Ixazomib Based Therapy in Multiple Myeloma: An Observational Study from China
    Li, Jing
    Zhuang, Jingli
    Wei, Zheng
    Ji, Liji
    Cheng, Zhixiang
    Liu, Peng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E265 - E265
  • [22] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [23] Real World Treatment Outcomes of Multiple Myeloma in Korea
    Byun, Ja Min
    Yoon, Sung-Soo
    Shin, Dong-Yeop
    Koh, Youngil
    Kim, Inho
    Kim, Hyun Kyung
    Lee, Dong Soon
    Lee, Jung-Lim
    Kim, Byung Su
    BLOOD, 2016, 128 (22)
  • [24] Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience
    Aqeel, Sheeba Ba
    Taneja, Alankrita
    Groman, Adrienne
    Parker, Sarah
    Jatwani, Karan
    Roy, Arya Mariam
    Attwood, Kristopher
    McCarthy, Philip L.
    Hillengass, Jens
    BLOOD, 2022, 140 : 13216 - 13217
  • [25] Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark
    Abildgaard, Niels
    Waage, Anders
    Hansson, Markus
    Anttila, Pekka
    Szilcz, Mate
    Ma, Yuanjun
    Rubin, Katrine Hass
    von Arx, Lill-Brith
    Orstavik, Sigurd
    Bent-Ennakhil, Nawal
    Freilich, Jonatan
    Gavini, Francois
    Green, Anders
    BLOOD, 2019, 134
  • [26] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [27] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    Kim, Hye Ryeon
    Min, Chang-Ki
    Lee, Je-Jung
    Shin, Ho-Jin
    Jo, Jae-Cheol
    Lee, Ji Yun
    Moon, Joon Ho
    Kim, Kihyun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 225 - 235
  • [28] Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma
    Sokol, Juraj
    Guman, Tomas
    Chudej, Juraj
    Hlebaskova, Monika
    Stecova, Natalia
    Valekova, Lubica
    Kucerikova, Monika
    Stasko, Jan
    ANNALS OF HEMATOLOGY, 2022, 101 (01) : 81 - 89
  • [29] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Ji Hyun Lee
    Sung-Hyun Kim
    Hye Ryeon Kim
    Chang-Ki Min
    Je-Jung Lee
    Ho-Jin Shin
    Jae-Cheol Jo
    Ji Yun Lee
    Joon Ho Moon
    Kihyun Kim
    International Journal of Hematology, 2023, 117 : 225 - 235
  • [30] Ixazomib-Based Maintenance Therapy Improves Prognosis of Patients with Multiple Myeloma: A Real-World Study
    Hong, Xiuli
    Chen, Jie
    Lu, Jingyuan
    Lu, Quanyi
    BLOOD, 2024, 144 : 7014 - 7015
12345